Cellarity Pitch Deck: All 12 Slides + Teardown

Cellarity's Series C pitch deck is a sophisticated example of how to market a 'platform-first' biotech company. Rather than leading with a single blockbuster drug candidate, the deck emphasizes a proprietary methodology that combines systems biology and machine learning to study cell behavior in its entirety. By shifting the focus from narrow molecular targets to holistic cellular health, Cellarity positions itself as a paradigm shift in the industry. The deck effectively uses visual metaphors for data mapping and provides a clear validation roadmap across multiple therapeutic areas, includin…

Key takeaways

• The company positions its technology as a 'radically new approach' that captures cellular changes at the single-cell level (Slide 3).
• Cellarity moves away from the traditional 'classic drug discovery' model of individual target identification to a model of 'encoding biology' (Slide 9).
• The proprietary platform is divided into three distinct pillars: Cellarity Map, Intervention Library, and Drug Design Studio (Slide 5).
• The deck showcases a broad pipeline covering Metabolic Disease, Hematology, Immuno-Oncology, and Respiratory sectors (Slide 7).
• Validation is clearly tracked across three stages: In Vitro, In Vivo, and NHP (Non-Human Primate), showing significant progress in insulin sensitization and hemoglobinopathy (Slide 7).
• The team slide is exceptionally dense, featuring 13 executive leaders and 8 board members/founders, emphasizing deep institutional experience from Novartis, Pfizer, and Biogen (Slide 11).
• The visual identity relies on complex data visualizations to represent 'cell dysfunction' as a topographical map, reinforcing the high-tech nature of their data (Slide 5).
• As reported by Business Insider, the company successfully raised $121M in 2024 following this Series C presentation.

Frequently asked questions

What is the core difference between Cellarity and traditional biotech?

According to Slide 9, traditional discovery focuses on individual target identification via high-throughput screening. Cellarity uses a 'new drug discovery paradigm' that encodes biology to see cell behavior in full, engineering therapies to change that behavior rather than just hitting a single protein target.

How does Cellarity demonstrate that its platform actually works?

Slide 7 provides a validation matrix. It shows that their programs for Insulin Sensitization and Hemoglobinopathy have already reached NHP (Non-Human Primate) validation, while others like T-Cell Exhaustion have completed In Vivo testing.

What are the three steps of the Cellarity platform?

Slide 5 outlines the process: 1) Cellarity Map to identify cell dysfunction, 2) Intervention Library to evaluate how different interventions affect that dysfunction, and 3) Drug Design Studio to optimize New Chemical Entities (NCEs).

Who is behind Cellarity?

The company is a Flagship Pioneering company. Slide 11 lists a massive team including CEO Fabrice Chouraqui (former President of Novartis Pharma US) and Co-Founder Noubar Afeyan (CEO of Flagship Pioneering).

Does the deck mention specific diseases they are treating?

Yes, Slide 7 lists specific indications: Insulin Sensitization, Energy Wasting, Hemoglobinopathy, Chemotherapy-Induced Thrombocytopenia, Myelofibrosis, T-Cell Exhaustion, and Goblet Cell Hyperplasia.

Cellarity pitch deck: the facts

Company

Cellarity

Year

2024

Stage

Series C

Slides

12

Sector

Biotech

Deck type

Series C Pitch Deck

Outcome

$121M Raised

Headquarters

North America

Cellarity pitch deck PDF

The full Cellarity deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Cellarity pitch deck was used for

This deck is a late-stage fundraising presentation by Cellarity, a Flagship Pioneering–founded biotech that discovers drugs by modeling and engineering cell behavior instead of single targets.[3][11][14] It was used for the company’s **Series C** financing, in which Cellarity raised **$121M** to grow its team, strengthen its cell-centric platform, and advance its pipeline toward the clinic in metabolic and blood disorders.[1][2][5][7][9][12] The slides emphasize the Cellarity platform (Cellarity Maps, intervention library, and drug design studio) and a broad preclinical pipeline across metabolic disease, hematology, immuno-oncology, and respiratory indications, positioning the round as capital to push multiple programs toward first-in-human trials.[2][5][7][14]

Business model: Cellarity is a biotechnology company developing medicines by targeting **cell behavior** rather than single molecular targets, using single-cell technologies, multi-omics data, and machine learning to digitize and map cellular network states and design therapeutics that correct dysfunctional cell states.[3][6][11][14][15]

Round

Series C later-stage venture financing.[1][2][5][7][9][12]

Raised

$121M.[1][2][5][7][9][12]

Lead investor

Flagship Pioneering.[2][7][9][10]

Investors

Flagship Pioneering, Kyowa Kirin Co. Ltd., Hanwha Impact Partners, Other prior Series B investors (including BlackRock, The Baupost Group, Banque Pictet) participated but are not individu

Founded

2017[3][6]

Headquarters

Cambridge, Massachusetts, USA.[5][14]

Industry

Biotechnology / Drug Discovery.[3][5][6][11][14][15]

Year: 2022 (Series C announced October 4, 2022).[1][2][5][7][9][12]

Total funding: $274M in total funding raised across rounds including a $123M Series B and a $121M Series C.[1][2][5][7][9][12][13][14]

Use of funds as presented: To grow Cellarity’s talent base, further develop and validate its cell-centric drug discovery platform, and advance pipeline programs—especially in metabolic disease and hematology—toward clinical testing.[2][5][7][9][14]

What happened after the Cellarity deck

Following its unveiling by Flagship Pioneering in 2019, Cellarity has raised $274M across Series B and Series C rounds to scale its AI-enabled, single-cell-based platform and move a multi-indication pipeline toward the clinic; as of the latest funding coverage, programs remain preclinical but are progressing toward initial clinical studies.[2][5][7][8][9][12][14]

• Completion of a **$123M Series B** round in February 2021 to advance multiple cell-behavior–based programs toward the cl
• Publication of a high-profile **Nature Biotechnology** paper on generalized RNA velocity, with staff featured on the fro
• Completion of a **$121M Series C** financing announced October 2022, bringing total funding to $274M and enabling platfo

What the Cellarity deck got right

• Compelling, differentiated cell-centric discovery paradigm. The deck articulates a **distinctive scientific thesis**: targeting cell behavior and network states, not single molecular targets, supported by single-cell technologies and machine learning, which clearly differentiates Cellarity from conventional target-based discovery.[3][6][11][14]
• Well-defined end-to-end platform architecture. Slides 3–5 present a structured platform (Cellarity Maps, intervention library, drug design studio) that connects data capture, intervention testing, and NCE design, giving investors a clear view of how the company turns biological insight into drug candidates.[3][6][11][14]
• Diverse, multi-indication pipeline tied to a unifying mechanism. Slide 7 and 8 show a **broad pipeline** across metabolic disease, hematology, immuno-oncology, and respiratory indications, with in vitro and in vivo validation and vanguard programs used to prioritize and de-risk additional indications, signaling platform breadth and scalability.[2][5][7][14]
• Strong external scientific and financial validation. The deck includes notable **external validation**: large prior financings (Series B $123M), recognition in Fierce Biotech’s “Fierce 15,” and a Nature Biotechnology front-page paper on generalized RNA velocity, which collectively strengthen credibility for a novel platform.[8][10][14]
• Clear narrative contrast with conventional drug discovery. By contrasting a classic target-based approach with the Cellarity approach (Slide 4) and emphasizing that cells are “the smallest unit of biological computation,” the narrative convincingly explains why their methods may offer better representation of disease and potential for non-intuitive interventions.[3][11][14]
• Demonstrated early pipeline velocity across indications. The deck highlights that programs have progressed quickly across multiple disease areas since launch (Slide 7’s “breadth and speed of our progress”), supporting the claim that the platform can generate assets efficiently once data and models are in place.[2][5][7][14]

What could have been stronger

• Limited quantitative evidence for the claimed increase in clinical translatability. The deck prominently claims that the platform will deliver “higher translatability and clinical success” based on cell-centric modeling, but provides no quantitative data, historical success metrics, or case studies (e.g., animal model outcomes, cross-indication validation rates) to substantiate this assertion.[2][3][11][14]
• Pipeline progress not clearly tied to specific development stages. Although Slide 7 lists multiple programs (insulin sensitization, energy wasting, hemoglobinopathy, chemotherapy-induced thrombocytopenia, myelofibrosis, T-cell exhaustion, goblet cell hyperplasia) with in vitro and in vivo validation, the deck—at least in the text we have—does not specify program stage (e.g., IND-enabling, Phase 1 timing), which can make it harder for investors to assess near-term milestones and risk profile.[14]
• Sparse competitive and market context for the platform. The deck repeatedly positions Cellarity as creating “medicines not possible today” via a “radically new” cell-wide approach, but offers limited competitive landscape analysis or differentiation against other AI-enabled and single-cell–based discovery platforms, which many late-stage investors will expect.[3][6][11][14]
• Regulatory and operational strategy under-explained for a nonstandard paradigm. While the platform architecture is described (Cellarity Maps, intervention library, drug design studio), the deck text we have does not detail regulatory, data, or manufacturing strategies (e.g., how novel cell-behavior–based endpoints will interact with regulators), an important risk area for an unconventional discovery paradigm.

How an investor would read this deck

What draws attention

• Evidence that the cell-centric platform can generate drug candidates with **clear advantages** over target-based approaches (e.g., efficacy in complex diseases, ability to rescue failed mechanisms).
• Quality and maturity of preclinical data across the listed programs—particularly in metabolic disease and hematology—and any impending **IND or first-in-human** milestones aligning with Series C capital deployment.[2][5][7][14]
• Scalability of Cellarity Maps, intervention library, and drug design studio: how quickly can new indications be added, and what are the bottlenecks (data generation, model training, chemistry throughput)?[3][6][11][14]
• Evidence of durable **IP and data moats** around the Cellarium, single-cell datasets, and AI models underpinning cell behavior mapping.[3][6][11][14]
• Partnership potential with pharma for co-development or platform access deals, which could provide non-dilutive capital and external validation of the paradigm.[3][5][11][14]

Risks that stand out

• Platform and biological risk: despite strong conceptual rationale, cell-behavior–based discovery is relatively unproven in the clinic; success depends on demonstrating that complex network interventions translate into safe, effective medicines in humans.[3][6][11][14]
• Execution risk: the strategy relies on sophisticated integration of high-dimensional single-cell data, AI modeling, and medicinal chemistry; scaling this reliably across many indications demands exceptional talent and infrastructure.[3][6][11][14]
• Regulatory risk: regulators may require additional evidence and novel endpoints to assess interventions driven by cell-behavior maps, potentially lengthening development timelines or complicating trial design.
• Competitive risk: other AI-enabled and single-cell–based drug discovery platforms may pursue overlapping indications, eroding first-mover advantages if Cellarity cannot rapidly progress programs.[3][6][11][14]
• Financing risk: as of the Series C, programs are preclinical; any delays in reaching human proof-of-concept could necessitate further funding before value-inflection events.[2][5][7][9][14]

Questions this deck invites

• For at least one lead program (e.g., a metabolic or hematology asset), what concrete preclinical endpoints (efficacy, safety, mechanistic biomarkers) have been achieved, and how do they compare with standard-of-care or competing approaches?
• How does Cellarity quantitatively demonstrate that its cell-behavior–centric approach improves **translation** from model systems to human disease versus traditional target-based discovery (e.g., retrospective analyses, predictive performan
• What is the current and projected timeline for first **IND filings** and **Phase 1 trials** for the vanguard programs supported by this Series C round?[2][5][7][9][14]
• How is the Cellarium and its underlying data curated, labeled, and updated, and what governance exists around data quality, reproducibility, and bias in AI-driven maps?[3][6][11][14]
• What specific IP (patents, trade secrets, exclusive datasets) protects Cellarity’s platform and differentiates it from other single-cell / AI drug discovery companies?[3][6][11][14]

What founders can take from the Cellarity deck

• A clear, **cell-centric thesis**—that cells are closer representations of disease than single molecular targets—can anchor an entire deck and differentiate a discovery platform in a crowded AI-biotech landscape.[3][6][11][14]
• Structuring the platform into named components (Cellarity Maps, intervention library, drug design studio) helps investors understand a complex workflow from data capture to drug design and where value is created.[3][6][11][14]
• Connecting a broad pipeline (metabolic, hematology, immuno-oncology, respiratory) back to a single unifying mechanism—cellular dysfunction mapping—shows platform breadth while reinforcing a coherent scientific story.[2][5][7][14]
• Highlighting external recognition (major financings, top biotech lists, a Nature Biotechnology front-page paper on RNA velocity) can bolster credibility of a novel paradigm when clinical proof-of-concept is still pending.[8][10][14]
• Explicitly contrasting the classic target-based approach with the Cellarity approach (slide 4) clarifies how the new paradigm differs and why it may solve problems traditional methods struggle with.[3][11][14]
• Demonstrating in vitro and in vivo validation across multiple programs, even prior to human data, can reassure late-stage investors that the platform has generated tangible, testable assets.[2][5][7][14]

Cellarity pitch deck: common questions

What does Cellarity do?

Cellarity is a Flagship Pioneering–founded biotech company that develops medicines by targeting **cell behavior** rather than individual molecular targets, using single-cell technologies and machine learning to understand and redirect cellular network states.[3][6][11][14]

How much did Cellarity raise in the Series C round, and when?

Cellarity’s **Series C** financing was a **$121M** later-stage VC round completed on **October 4, 2022**, bringing its total funding to **$274M**.[1][2][5][7][9][12] Existing Series B investors (including Flagship Pioneering) participated along with four new investors, including **Kyowa Kirin Co. Ltd.** and **Hanwha Impact Partners**.[2][7][9][10]

Who invested in Cellarity’s Series C round?

The Series C round was led by **Flagship Pioneering** and included participation from prior Series B investors and four new investors, among them **Kyowa Kirin Co. Ltd.** and **Hanwha Impact Partners**; additional investors were not publicly named.[2][7][9][10][13]

What was the Series C funding intended to be used for?

According to the financing announcements, Cellarity is using the Series C proceeds to grow its talent base, further build out and validate its cell-centric discovery platform, and advance its pipeline programs—particularly in **metabolic disease** and **hematology**—toward clinical testing.[2][5][7][9][14]

Which therapeutic areas and programs are featured in Cellarity’s deck?

The Series C deck highlights a pipeline spanning **metabolic disease** (e.g., insulin sensitization, energy wasting), **hematology** (e.g., hemoglobinopathy, chemotherapy-induced thrombocytopenia, myelofibrosis), **immuno-oncology** (T-cell exhaustion), and **respiratory** (goblet cell hyperplasia), with validation in vitro and in vivo and programs launched by Q4 2021.[14] These programs are based on identifying and correcting specific cellular dysfunctions across different tissues.

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Cellarity's $121M Raise Signals A Promising Drug ...
• Cellarity closes $121M financing, uses single-cell technologies to ...
• Flagship Pioneering Unveils Cellarity, the First Company to Discover ...
• Cellarity IPO Timeline and Financing Details
• A Flagship startup secures $121M in new funding - BioPharma Dive
• Flagship Pioneering launches Cellarity for cell behaviour- ...
• Flagship-founded Cellarity closes $121M series C round
• Cellarity Raises $123 Million in Series B Funding to Pioneer a New ...

Cellarity pitch deck slides

What each slide of the Cellarity pitch deck says

Slide 1

ae va 4 Encoding biology, Aro, A engineering breakthrough medicines EZ Cellarity==

Slide 2

Jl This presentation contains forward-looking statements regarding the Cellarily's plans, outlook, strategies and resulls for the future. All forward-looking statements are based on judgments derived from the information available to Cellarity at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate,” "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," "intend" or other similar words or expressions of the negative thereof. | | Certain risks and uncertainties could cause Cellarity’s actual results to differ materially from any forwa…

Slide 3

CELLARITY - CREATING MEDICINES NOT POSSIBLE TODAY » Cellarity is driving a radically new approach to drug discovery by working at the confluence of system biology, high-resolution data, and machine learning » We understand disease biology by capturing the broad spectrum of cellular changes at the single cell level, instead of focusing on a specific molecular target » This approach allows us to uncover novel biology and predict non-intuitive pharmacological interventions » Because cells are closer representations of disease than molecular targets, our platform is designed to deliver higher translatability and clinical success Cellarity== A Flagship Pioneering Company

Slide 4

MOVING FROM A A TRANSFORMATIVE CELL-CENTRIC APPROACH = lEUChDREES PURPOSEFUL APPROACH CELL-WIDE PERSPECTIVE * The cell is the smallest unit of biological computation \ « We see biological system in full, not through the BN >4 M ! g \Qr/ proxy of a single target « We identify the changes that underly the start and progression of a disease SINGLE TARGET e » We purposefully engineer therapies that address theses changes Classic target-based approach Cellarity approach Cellarity== A Flagship Pioneering Company

Slide 5

CELLARITY'S UNIQUE PLATFORM o 24 (34 CELLARITY MAP INTERVENTION LIBRARY DRUG DESIGN STUDIO Identify cell dysfunction Evaluate interventions Design and optimize NCEs 4 N STRUCTURE © o NETWORK PROTEIN L 1] Identify changes as a cell l«l' RN moves from a state of health Evaluate interventions that can Engineer NCEs with higher to a state of disease address cellular dysfunction probabilities of clinical success Cellarity== A Flagship Pioneering Company

Slide 6

CELLARITY’S PLATFORM ALREADY DELIVERED MULTIPLE GAME CHANGING OPPORTUNITIES HbAlc Fold Increase in Red Cells Expressing HbF ABIPAS Staining (Mucus) " . . Ip c Y 0 cuss 8 TT 2 wi 1 26 . Diabetic = 2 . alle Vg N . fa sis 7 ee or Fo —" o* SP ee SEP Ron gl & - ——38 Non-Disbetic 458 an, £7 o Bascire Swi 12vks 10 20 30 Fell % = So ae Treating sickle cell disease Insulin sensitizing distinct with a small molecule Preventing lung cell damage

Slide 7

BREADTH AND SPEED OF OUR PROGRESS HIGHLIGHT THE POWER OF THE CELLARITY PLATFORM Program Deep Dives METABOLIC DISEASE HEMATOLOGY IMMU NO ONCO! RESPIRATORY % 0 V) 0 & & LVER Insulin Sensitization Energy Wasting Hemoglobinopathy Chemotherapy-Induced Thrombocytopenia Myelofibrosis T-Cell Exhaustion Goblet Cell Hyperplasia VALIDATION IN VITRO IN VIVO Program Launched Q4 2021 Cellarity== A Flagship Pioneering Company

Slide 8

CELLARITY'S PLATFORM IS DESIGNED TO UNLOCK TREATMENTS IN VIRTUALLY EVERY DISEASE Nepiwclogy PIPELINE STRATEGY BASED ON VANGUARD PROGRAMS TO PRIORITIZE AND DE-RISK Diseases linked to a specific cellular dysfunction found within a single cell type Diseases with more than a single form of . cellular dysfunction, but simplifying elements such as location to single organ Diseases with poorly understood . pathophysiology, likely representing multiple forms of cellular dysfunction across multiple cell types & NHP validation ' Follow on programs Cellarity== A Fiagship Pioneering Company

Slide 9

CELLARITY IS BUILDING AN ENTIRELY NEW APPROACH TO THERAPEUTIC DEVELOPMENT New drug discovery paradigm Encoding biology to see cell Al-enabled %Ej% behavior in full drug discovel 9 4 « Purposefully engineering Classic drug (O discovery CD therapies to engender desired changes in cell behavior Al augmenting Individual target classic approaches in identification supported by target identification H high throughput screening Cel ar ty— Cellarity== A Flagship Pioneering Company

Slide 10

CELLARITY BECOMING RECOGNIZED AS A TRANSFORMATIVE BIOTECH > W This Startup Just Raised $123 IEOOIEN Million'To bevelop A New Way To Find Medicine #rierce Cellarity nets $123M to drive cell behavior pipeline toward clinle Cellarity announces completion of Series B with contribution of world leading investors such as BlackRock, Baupost Group, Banque Pictet, and Ahren Innovation Capital Volume 38 Issue 12, December 2020 RNA velocity fully solved Staff were recognized on the front page of Nature Biotechnology in a landmark paper, generalizing RNA velocity to transient cell states through dynamical modeling FIERCE 15 Cellarity recognized as a top biotech, by sources including Fierce Biotech (Fie…

Slide text above is read directly from the Cellarity deck PDF embedded on this page.

Related fundraising guides (24)

• Hint Health Pitch Deck Teardown: Scaling Direct Primary Care Infrastructure
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI
• Bringg Pitch Deck Teardown: A Masterclass in Enterprise SaaS Traction and Scale
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• Green Li-ion Pitch Deck Teardown: A Masterclass in Supply Chain Disruption for Battery Recycling
• Cowboy Pitch Deck Teardown: A Masterclass in High-End Lifestyle Branding and Urban Mobility
• authID.ai Pitch Deck Teardown: A Post-IPO Roadmap for Biometric Identity Verification
• Limetree Pitch Deck Teardown: A Case Study in Early-Stage Family Media Preservation
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Equinom Pitch Deck Teardown: Solving the 250% Plant-Based Cost Gap Through Seed Genetics
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Cube Pitch Deck Teardown: A $30M Series B Masterclass in Narrative Simplicity
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Nest Health Pitch Deck Teardown: A $15M Seed Strategy for Value-Based Family Care
• Include Pitch Deck Teardown: Scaling Smart City Infrastructure Through Global Distribution
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Heura Pitch Deck Teardown: Dominating the Mediterranean Plant-Based Market

Decks from the same year (1)

• 2024 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $50M to $250M

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

More pitch deck teardowns (16)

• Cardiff International Pitch Deck Teardown: A Conglomerate Strategy for OTC Micro-Caps
• CDIF Pitch Deck Teardown: The Micro-Cap Holding Company Roll-Up Strategy
• Cobre del Mayo Pitch Deck Teardown: A Deep Dive into Copper Mining Yield and Risk
• Cobre Del Mayo Pitch Deck Teardown: A Deep Dive into Copper Mining Operational Turnarounds
• Cedar Fair Pitch Deck Teardown: Leveraging Real Estate and Yield in Entertainment
• Cedar Pitch Deck Breakdown: Solving the $345B Healthcare Billing Crisis
• CeIR Pitch Deck Teardown: A Hybrid EdTech and Infrastructure Play in Zambia
• Celer Network Pitch Deck Breakdown: A Visual Masterclass in Layer-2 Blockchain Infrastructure
• CellBreaker Pitch Deck Breakdown: A Minimalist Approach to Consumer Justice
• Celsius Network Pitch Deck Teardown: The Ideological Play for Crypto Lending Dominance
• Celsius Network Pitch Deck Breakdown: A Visionary Narrative for Crypto Lending
• Celsius Pitch Deck Teardown: Scaling a Functional Beverage Brand via Global Distribution
• Cematrix Pitch Deck Teardown: Proving Industrial Scale Through Infrastructure Case Studies
• CENOS Pitch Deck Breakdown: Democratizing Industrial Simulation for SMBs
• Cent Capital Pitch Deck Teardown: A B2B2C Strategy for AI-Powered Financial Wellness
• Centric Health Pitch Deck Teardown: Consolidation Strategy in Canadian Seniors Pharmacy

Recently published pitch deck teardowns (12)

• Tiun Pitch Deck Teardown: A $2.5M Masterclass in Minimalist B2B Infrastructure Storytelling
• Treble Pitch Deck Teardown: Scaling Synthetic Audio Simulation to €1.3M ARR
• Toch.ai Pitch Deck Teardown: A Product-First Look at AI Video Automation
• Uncaged Innovations Pitch Deck Teardown: A $5.6M Seed for Grain-Based Bio-Leather
• Uplift Labs Pitch Deck Teardown: A $5.5M Seed Round Built on Biometric Data and Elite Pedigree
• Upstream Pitch Deck Teardown: A Minimalist Approach to Professional Networking
• Valuecase Pitch Deck Teardown: A $3.5M Pre-Seed Masterclass in Digital Sales Rooms
• Vibrant Planet Pitch Deck Teardown: A Data-Driven Approach to Wildfire and Climate Resilience
• Vibranium Labs Pitch Deck Teardown: A $4.6M Seed Round Built on SRE Pedigree
• Vestwell Pitch Deck Teardown: A $70M Masterclass in Market Dominance and Scale
• Volocopter Pitch Deck Teardown: Selling the Infrastructure of Urban Air Mobility
• Voxel Pitch Deck Teardown: A Masterclass in Visualizing Invisible Industrial Risk

Fundraising library · Pitch deck examples · Investor directory · Founder database